Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Primovist Approved in the US: Bayer HealthCare
August 4, 2008
- TOPICS／JADEC, sanofi-aventis Cosponsor HbA1c Awareness Enhancement Campaign
August 4, 2008
- PMDA Receives Highest Rating Regarding Balance of Payment, Relief of ADR Victims
August 4, 2008
- Korosho Requires Makers of MTX to Take New Measures to Prevent Overdosing
July 28, 2008
- BUSINESS NEWS IN BRIEF
July 28, 2008
- Korosho Shows Interest in GPOs of the US
July 28, 2008
- JPLA SEMINAR
July 28, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 28, 2008
- Average Wage Hike \5,949 in 2008
July 28, 2008
- Gefitinib Beneficial for Adenocarcinoma Regardless of Smoking History
July 28, 2008
- Pfizer to Develop Market for Sutent as First-Line Therapy for RCC
July 28, 2008
- Clopidogrel May Be Less Effective in Japanese than in Westerners
July 28, 2008
- Eisai Develops Add'l Indications, Dosage Forms for Aricept as Part of Life Cycle Management
July 28, 2008
- Korosho Presents Draft Vision for Medical Devices Industry
July 28, 2008
- Kyowa Hakko, Lonza Extend Their Strategic Collaboration
July 28, 2008
- Asahi Kasei to Enter Market for Advanced Medical Devices
July 28, 2008
- Nichi-Iko Aims at Becoming World Top-10 Generic Maker
July 28, 2008
- GENERICS NEWS IN BRIEF
July 28, 2008
- Korosho Announces Drug Dispensing Fees per Prescription for the First Time
July 28, 2008
- Sawai to Focus on Drugs for Lifestyle Diseases
July 28, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…